On August 21, 2025, the U.S. FDA approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2 to F3). This marks a significant expansion of Wegovy's therapeutic indications.
This approval makes Wegovy the first and only GLP-1 treatment approved for MASH, a condition affecting one in three people with overweight or obesity. The ESSENCE trial demonstrated statistically significant and superior improvements in both MASH resolution and liver fibrosis.
The new indication opens a substantial new market opportunity for Novo Nordisk, addressing a vast unmet medical need. This strategic approval reinforces Wegovy's versatility and strengthens Novo Nordisk's leadership in metabolic health beyond just weight loss.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.